EHD3 and colorectal carcinoma: To further determine EHD3 hypermethylation in CRC from the TCGA dataset, this study analyzed the correlation of the treatment outcomes of antimetabolites, DNA alkylating drugs, and topoisomerase inhibitors with the methylation level of the EHD3 promoter region.